Skip to content

Study · Other design · n = 60 · 2014

4 results

[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].

Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2014Cited by 1 (Europe PMC)

PMID25176261 (opens in a new tab)PepBankPUB-25176261
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanOther designEfficacy outcome

    In patients with phobic-anxiety and somatoform disorders, a pronounced anxiolytic effect of selank was demonstrated.

    In plain wordsIn patients with anxiety-type disorders, selank showed a pronounced anti-anxiety effect.

    Peptide
    Selank
    Outcome
    Not applicableAnxiolytic effect
    Study

    n = 60

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results Pronounced anxiolytic and mild nootropic effects of selank were demonstrated.
    1 context sentence
    Summary · context
    A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined.
  2. 02HumanOther designEfficacy outcome

    In patients with phobic-anxiety and somatoform disorders, a mild nootropic effect of selank was demonstrated.

    In plain wordsIn patients with anxiety-type disorders, selank showed a mild effect on thinking and memory.

    Peptide
    Selank
    Outcome
    Not applicableNootropic effect
    Study

    n = 60

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results Pronounced anxiolytic and mild nootropic effects of selank were demonstrated.
    1 context sentence
    Summary · context
    A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined.
  3. 03HumanOther designEfficacy outcome

    In patients with phobic-anxiety and somatoform disorders, the anxiolytic effect of selank lasted for a week after the last dose.

    In plain wordsIn patients with anxiety-type disorders, the anti-anxiety effect of selank lasted for a week after the last dose.

    Peptide
    Selank
    Outcome
    Not applicableDuration of anxiolytic effect after last dose
    Study

    n = 60

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The anxiolytic effect lasted for a week after last receiving the peptide.
    1 context sentence
    Summary · context
    A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined.
  4. 04HumanOther designEfficacy outcome

    In patients with phobic-anxiety and somatoform disorders, selank had a positive impact on quality of life.

    In plain wordsIn patients with anxiety-type disorders, selank had a positive effect on quality of life.

    Peptide
    Selank
    Outcome
    IncreaseQuality of life
    Study

    n = 60

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Selank had a positive impact on the quality of life of the patients.
    1 context sentence
    Summary · context
    A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.